Blood Test Panel Shows Promise for Liver Cancer

Adults with chronic liver disease may eventually benefit from earlier detection, though the panel has not yet been tested prospectively.

Updated on Nov. 6, 2026 in Cancer

Bold flat-color editorial illustration of a clear blood-sample vial of crimson liquid beside a pale ochre liver-shaped form on a plain surface.
Researchers developed a six-biomarker blood test that distinguishes liver cancer from chronic liver disease, though it has not yet been tested prospectively. AI Illustration. Upload story photo >

Researchers have developed a blood test panel combining six biomarkers that distinguishes hepatocellular carcinoma, the most common type of liver cancer, from chronic liver disease. The model was built in populations predominantly affected by hepatitis B and has been tested in case-control studies, so it remains experimental for now.

Why it matters

Liver cancer is often caught late, and the tools used for surveillance in people with chronic liver disease have limits in detecting early tumors. A blood-based panel that performs well in early-stage disease could, if validated prospectively, support earlier detection in people already under liver monitoring, though it is not yet ready for routine clinical use.

This is a case-control diagnostic study that used genome-wide DNA methylation profiling of 55 liver tumor tissues and matched non-tumor tissues, then assessed candidate markers in 299 blood samples and validated the model in an independent cohort of 149 participants. The panel reached 88.4% sensitivity and 93.8% specificity in validation, and because it is a case-control design, real-world performance remains to be confirmed.

The details

The panel pairs four DNA methylation markers, which are chemical tags on DNA that change as tumors develop, with two protein markers measured in the blood. Researchers first mapped methylation patterns across tumor and non-tumor liver tissue, then tested which markers still separated cancer from disease when measured in blood. Because the model was built mostly in people with hepatitis B, its accuracy in other causes of liver disease has not been established.

Timeline

  1. The study's publication date was not specified in the source material.

Health Landscape

Alpha-fetoprotein and des-gamma-carboxyprothrombin have been the blood markers used to monitor liver cancer, and this panel reported better performance than both in a case-control setting. The result adds to a broader effort to replace single protein markers with multi-marker models, though it still requires prospective testing before it could change standard surveillance.

If you have chronic liver disease, including hepatitis B, it is worth asking your doctor what liver cancer surveillance you currently receive and whether newer blood-based tests might be relevant in the future. This research is at an early stage, so no changes to existing screening should be made based on it alone.

The takeaway

A multi-marker blood panel showed strong accuracy for liver cancer in early research, but prospective validation is still needed. If you have chronic liver disease, discuss your current surveillance plan with your physician.

Further reading

For more on how these tests are being developed, explore our Cancer coverage.